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ABSTRACT
Objective: To assess the effect of second-generation antide-
pressants on mania-related and depression-related ofﬁce vis-
its for adults with bipolar disorder.
Methods: Using a national managed-care claims database,
we retrospectively identiﬁed continuously enrolled patients
with bipolar disorder who had a new antidepressive prescrip-
tion treatment between January 1998 and December 2002.
Patients were followed for at least 12 months after the date
of initial use of antidepressant monotherapy, mood stabilizer
monotherapy, or antidepressant–mood stabilizer combina-
tion therapy. Logit models with propensity score matching
were used to identify the relationship between treatment
types and the likelihood of having mania-related visits
within  12 months.  Negative  binomial  models  and Cox pro-
portional hazard  models  were  used  to  predict  the  number
of depression-related visits and time to ﬁrst mania- or
depression-related visit.
Results: Patients on antidepressant monotherapy and com-
bination therapy did not have different likelihoods of mania-
related visits compared with those on mood stabilizer mon-
otherapy (with odds ratios (ORs) 0.67 (95% conﬁdence
interval (CI) 0.42–1.04) and 0.99 (95% CI 0.69–1.43),
respectively). The numbers of depression-related visits for the
same comparisons were signiﬁcantly lower, with incidence
rate ratios of 0.68 (95% CI 0.56–0.82) and 0.65 (95% CI
0.52–0.81), respectively. The results of time to ﬁrst mania- or
depression-related visit provided similar indications.
Conclusions: Second-generation antidepressant was associ-
ated with a decreased number of depression-related visits
but was not associated with an increased risk of mania-
related visits within a 1-year period. Although more work
is needed to establish the safety and efﬁcacy of second-
generation antidepressants in treating bipolar depression,
the evidence from this study supports a favorable risk–
beneﬁt proﬁle.
Keywords: bipolar depression, bipolar disorder, manic-
switching, propensity score, second-generation
antidepressant.
Introduction
Bipolar disorder, also referred to as manic-depressive
illness, is a severe psychiatric recurrent mood disorder
characterized by both depressive and manic or
hypomanic episodes with intervening periods of
euthymia (a return to normal functioning) [1]. Bipolar
disorder is ranked as one of the most costly mental-
health diseases [2] in terms of both the direct medical
costs of managing the condition and the indirect costs
associated with loss of work productivity and disrup-
tion of daily activities of both the sufferers themselves
and  their  family  members  and  caregivers  [3].  It  is
a major cause of disability worldwide. The World
Health Organization identiﬁed bipolar disorder as the
sixth leading cause of disability-adjusted life years in
the world among people aged 15 to 44 years, above
osteoarthritis, HIV, diabetes, and asthma [4].
Although mania and hypomania historically have
received extensive attention from medical researchers,
the depressed phase of bipolar disorder is a more sig-
niﬁcant cause of suffering, disability, and mortality.
Bipolar patients are estimated to spend more than
three times as long suffering from depressive symp-
toms than manic symptoms [5]. Compared with manic
phases, episodes of bipolar depression are more fre-
quent and last longer [6]. Depressive symptoms are the
primary determinant of health-related quality of life
in bipolar disorder [7]. Additionally, recovery from
depression is slower and less complete than recovery
from mania [8]. The lifetime risk of completed suicide
during bipolar depression is 30 times higher than that
of mania [9].
Most treatments for bipolar depression are based
on unsupported extrapolation from the treatment of
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unipolar depression or guidelines derived largely from
the clinical practice experience of experts in this ﬁeld
[10,11]. No sufﬁcient evidence was available to verify
the appropriateness of treatment guidelines in adults
on a large population basis. Speciﬁcally, current Amer-
ican Psychiatric Association (APA) practice guidelines
recommend that antidepressant (AD) monotherapy
not be considered for bipolar depression given the
potential risk of induced manic-switching and rapid-
cycling [11]. The combined use of mood stabilizer
(MS) drugs and ADs can be considered if the illness is
severe. Nevertheless, the risk associated with second-
generation ADs is not certain because not enough
information has been provided regarding this newer
group of medications.
Moller and Grunze from Germany [12] suggested
that modern ADs should be used as a ﬁrst-line treat-
ment for bipolar depression, which is contradictory to
the current APA guidelines. Although Europe might
have different treatment guidelines than the United
States, this controversy has inspired more discussion
[13], and additional research would provide more
information to determine whether second-generation
AD therapies are appropriate to use.
The aim of this study is to assess the effects of
different types of medication treatment—including
second-generation ADs—on mania-related and
depression-related ofﬁce visits as outcomes. We used
an intent-to-treat approach to evaluate three different
types of pharmacotherapy: AD monotherapy, MS
monotherapy, and AD–MS combination therapy.
Methods
Conceptual Framework
We developed our conceptual framework by following
the Andersen behavioral model for health service uti-
lization [14]. This conceptual framework guided our
choice of variables for the explanatory regression mod-
els. The Andersen model indicates that in order to
make a policy change, mutable variables such as ena-
bling factors should be the focus of attention. We
assessed the effects of prescribing behavior (types of
treatment with or without AD) on health outcomes
while simultaneously considering the inﬂuence of other
mutable enabling factors, including insurance plan,
type of medical providers, and geographic regions as
well as other enabling factors, including clinical-
related variables (e.g., concurrent use of other medica-
tions or psychotherapy).
The model for this study seeks to evaluate the
extent to which enabling factors (e.g., prescribing
behavior) affect consequential health service utiliza-
tion and health outcomes with simultaneous consider-
ation of previous-period health status (comorbidities),
which is indicated by need variables in the Andersen
model.
Data Source
Data were derived from the Integrated Healthcare
Information Services database, which is aggregated
from more than 30 managed-care health plans in the
United States. The data are organized into the follow-
ing ﬁve ﬁles: 1) member demographics and enrollment
information; 2) medical service utilization; 3) inpatient
conﬁnement utilization; 4) pharmacy claims; and 5)
laboratory results. All service utilization ﬁles provide
insurance claims-level account of health-care services
received by a patient, including visits with a physician,
medical procedures, inpatient stays, diagnostic tests,
and prescription drugs.
Medications of Interest
Medication treatments for bipolar depression were
classiﬁed as second-generation AD monotherapy, MS
monotherapy, or second-generation AD–MS combina-
tion therapy. To be consistent with the APA national
practice guidelines, AD monotherapy was deﬁned as
the use of ADs without MSs [11]. Patients were still
considered using AD monotherapy if they switched/
augmented to another brand of AD prescriptions.
Table 1 lists the second-generation ADs that were
included in the study. Anticonvulsants were catego-
rized as MS. Patients with antipsychotic use as an ini-
tial treatment were excluded because the focus of this
study is only AD without the case-mix of the antipsy-
chotics. Combination of antipsychotic use with ADs
might confound the results of a treatment type. Use of
benzodiazepines, sometimes added as ancillary treat-
ment for bipolar mania [10], was noted and treated as
a covariate. National Drug Codes codes were used to
identify all medications in the pharmacy ﬁle.
Inclusion and Exclusion Criteria
Subjects (aged 18–64 years) were included in the study
if they had at least one medical claim for bipolar dis-
order (International Classiﬁcation of Diseases, 9th
Edition (ICD-9): 296.4x−296.8x) between January 1,
1998 and December 31, 2002. Each subject must have
received at least one prescription for an MS or a sec-
ond-generation AD during the period. Patients were
required to have continuous prescription drug beneﬁt
and full mental-health information reported in the
database. Members with a comorbid diagnosis of epi-
Table 1 Second-generation antidepressants included in the
study for bipolar disorder
Subclass and name of the medications
• Selective serotonin reuptake inhibitors: citalopram, escitalopram, 
ﬂuoxetine, ﬂuvoxamine, paroxetine, sertraline
• Serotonin–norepinephrine reuptake inhibitors: venlafaxine
• Serotonin reuptake inhibitor: nefazodone, trazodone
• Dopamine reuptake inhibitor: bupropion
• Noradrenergic antagonist: mirtazapine
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lepsy (ICD-9: 345.xx) and/or schizophrenia (ICD-9:
295.xx) were excluded so that we would have reason-
able assurance that the prescriptions were used to treat
bipolar disorder [15].
To guard against false negative coding within the
claim database (i.e., bipolar depression coded as major
depression disorder (MDD)), any patient with a diag-
nosis of MDD (ICD-9: 296.2, 296.3, 311) that
occurred after the pure bipolar-related diagnosis
(296.0, 296.1, 296.4–296.8) or earlier but no more
than 90 days before the pure bipolar-related diagnosis
were deemed miscoded and considered bipolar
depression.
We attempted to identify a cohort of patients receiv-
ing a new episode of prescription drug treatment for
bipolar depression. The index date was deﬁned as the
ﬁrst dispensing date of either a second-generation AD
or an MS coupled with a depression-related diagnosis.
The MS with a depression-related diagnosis ensured
that such an MS was used for treating bipolar depres-
sion rather than bipolar mania. Patients were excluded
if they had one or more visits for a depression-related
diagnosis (296.82, 296.5, or miscoded 296.2, 296.3,
311 without remission) and/or received a prescription
claim for a second-generation AD within the 3-month
period before the index date. Patients must have had at
least 12 months of continuous enrollment after the
index date. As an intent-to-treat approach, the treat-
ment cohort was deﬁned by the ﬁrst 30-day use of ADs
and/or MSs after the index date.
Outcome Measures
Outcome variables were observed over the 12 months
after treatment was initiated. Based on the variable
distribution, the primary outcomes of the study
included whether a patient had any mania-related vis-
its and the number of depression-related visits within
12 months after the index date. Mania-related visits
were identiﬁed by ICD-9 codes 296.0x, 296.1x,
296.4x, or 296.81 using both the medical service and
inpatient conﬁnement utilization data. Depression-
related visits were identiﬁed by ICD-9 codes 296.5x,
296.82, or miscoded 296.2x, 296.3x, 311 (i.e., bipolar
depression was coded as MDD). Secondary outcome
variables included time from index to the ﬁrst mania-
related visit and time to the ﬁrst depression-related
visit.
Explanatory Variables
In addition to the medication use as interventional var-
iable, other explanatory variables were grouped into
demographic, clinical-related, and health-related fol-
lowing the conceptual framework. Demographic vari-
ables (i.e., age, sex) were used to deﬁne predisposing
characteristics. Enabling resources were conceptual-
ized as insurance type and geographic region. Insur-
ance type was categorized into health maintenance
organization, preferred provider organization, and
point of service as data provided.
Clinical-related variables included use of antipsy-
chotics, benzodiazepines, tricyclics, and monoamine
oxidase inhibitors in the 12 month follow-up period;
use of electroconvulsive therapy (ECT) and psycho-
therapy identiﬁed by Current Procedural Terminology
codes; and type of medical provider, categorized as
psychiatrist, internal medicine specialist, general/fam-
ily practitioner, and other. Health-related variables
included presence of selected comorbidities and the
Charlson Comorbidity index score [16]. The Charlson
Comorbidity index is a validated method to predict
future mortality from medical records, and it was used
as a surrogate measure for general health status.
Bipolar patients have a signiﬁcantly higher preva-
lence of diabetes mellitus than the average population
[17]. Therefore, diabetes was considered a comorbid
condition. Other comorbidities of interest included
substance abuse and other mental-health conditions.
Econometric Modeling
Our modeling strategy begins with a logistic regression
model to predict the likelihood of having mania-
related visits over the 12-month follow-up period, con-
trolling for the type of treatment, observed individual
demographics, clinical-related variables, health-related
variables during the treatment, and the baseline disease
severity of bipolar disorder. Because the baseline
disease severity of bipolar disorder cannot be truly
observed and the rating measures to assess the disease
severity (e.g., the Clinical Global Impression for Bipo-
lar Disorder (CGI-BP) scale) were unavailable in the
database, we used a proxy to control for disease sever-
ity—whether the patient had any mania-related visits
in the pre-index period. This proxy variable, however,
is simply a lagged dependent variable, which is endog-
enous and also a function of the true disease severity.
As a result, it could potentially lead to a biased
estimation.
To better balance the background characteristics
between groups, a propensity score approach was used
to predict the propensity to be in the AD-related treat-
ment groups (comparison 1: AD monotherapy vs. MS
monotherapy; comparison 2: AD–MS combination
therapy vs. MS monotherapy). Variables in the predic-
tive equation included individual demographics, clini-
cal-related variables, health-related variables, quarter
of the year when initiating the treatment, miscoding
of bipolar depression, and bipolar severity variables,
which included the number of mania-related visits,
number of any bipolar-related visits (mixed and
unspeciﬁed types also included), natural logarithm of
bipolar-related costs, and natural logarithm of total
health-care costs in the pretreatment period. After
achieving covariate balancing, the greedy matching
algorithm [18] was used with matching from best to
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next-best. Best matches were deﬁned as those with the
highest digit match (0.00001) on propensity score in
the study. The algorithm proceeded sequentially to the
lower digit match. The lowest allowable digit match
for the study was 0.1. The matched subsamples were
used as the analytic data set.
Based on the variable distribution, negative bino-
mial models were used when the outcome was the
number of depression-related visits. Cox proportional
hazard models were used when the outcomes were
time to ﬁrst mania- or depression-related visit. Both
the Cox proportional hazard model and the negative
binomial model were used with propensity score
matching after the control of potential confounding
variables described earlier.
Results
Descriptive Statistics
Of the 3737 patients in the ﬁnal sample, 2096 patients
were receiving AD monotherapy, 504 were receiving
MS monotherapy, and 1137 were receiving AD–MS
combination therapy at the index date. The proportion
of patients receiving AD monotherapy, MS mono-
therapy, and AD–MS combination therapy stayed
approximately the same over the 5-year analytic
period (i.e., 1998–2002). AD monotherapy accounted
for 40% to 51% of patients at any given year during
the study.
The percentages of patients having at least one
mania-related visit within 1 year after treatment initi-
ation were 12%, 22%, and 21% for AD monotherapy,
MS monotherapy, and AD–MS combination therapy,
respectively. The average numbers of depression-
related visits within the same period were 3.2, 4.6, and
3.1, respectively.
Explanatory Results
Table 2 shows the baseline characteristics of bipolar
patients who had AD monotherapy and MS mono-
therapy before and after the propensity score match-
ing. The matching resulted in more balanced groups in
terms of the measured covariates. All of the variables
that showed statistically signiﬁcant differences before
matching had no signiﬁcant differences after matching.
The same procedure was carried out for the propensity
score matching between patients with AD–MS combi-
nation therapy and MS monotherapy. The balancing
was achieved as well.
The full logistic regression results are reported in
Table 3 with propensity score-matched sample for the
two comparison pairs. The original coefﬁcient esti-
mates were exponentiated to derive odds ratios (ORs)
to characterize the effect of a unit change of each inde-
pendent variable on the probability of having mania-
related visits within the observed 12 months while
holding all other covariates constant. Table 3 indicates
that the odds of having mania-related visits for
patients with AD monotherapy were not signiﬁcantly
different from the odds for the patients on MS mono-
therapy (OR 0.67; 95% conﬁdence interval (CI) 0.42–
1.04). The indication was the same for the comparison
between combination therapy and MS monotherapy.
In addition, patients were more likely to have mania-
related visits after the index date if they had visits
before the index date with statistically signiﬁcant ORs
of 34.6 and 1.77 for comparison 1 and comparison 2,
respectively. Among clinical-related variables, use of
antipsychotics, psychotherapy, and ECT in the 12-
month follow-up period were all strong positive pre-
dictors of the likelihood of mania-related visits, with
ORs ranging from 1.85 to 2.94.
The negative binomial model (Table 4) showed that
patients on AD monotherapy and AD–MS combina-
tion therapy had signiﬁcantly lower rates of depres-
sion-related visits within 12-months after the index
date than the patients on MS monotherapy, with inci-
dence rate ratios of 0.68 (95% CI 0.56–0.82) and 0.65
(95% CI 0.52–0.81), respectively. To test the effect of
treatment on time to ﬁrst mania- or depression-related
visit in the secondary analysis, we used Cox propor-
tional hazard models with propensity score matching
(Table 4). Patients on AD monotherapy and AD–MS
combination therapy did not have signiﬁcantly differ-
ent time to ﬁrst mania-related visits compared with
patients with MS monotherapy, with hazard ratios of
0.83 (95% CI 0.60–1.16) and 1.08 (95% CI 0.82–
1.41), respectively. On the other side, time to ﬁrst
depression-related visit for those on AD monotherapy
and AD–MS combination therapy were signiﬁcantly
longer than the patients with MS monotherapy, with
hazard ratios of 0.55 (95% CI 0.44–0.68) and 0.59
(95% CI 0.48–0.73).
Discussion
Bipolar disorder is a severe, lifelong chronic illness
for which optimal treatment requires long-term man-
agement. The depressed phase of bipolar disorder is
a more signiﬁcant cause of suffering, disability, and
mortality, but it has been understudied and most
treatments are based on unsupported extrapolation
from the treatment of unipolar depression [19,20].
This article adds to the literature of bipolar depres-
sion treatment by providing additional empirical evi-
dence. Recent debate and discussion revealed that
the risk of manic-switching with second-generation
ADs is uncertain for the treatment of bipolar depres-
sion [12,13]. This study, which consisted of an
insured population, indicated that second-generation
AD (including monotherapy and AD–MS com-
bination therapy) was not related with a higher
likelihood of manic-switching compared with MS
monotherapy.
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The analysis of time to ﬁrst postindex mania-related
visit found no difference between AD monotherapy or
AD–MS combination therapy and MS monotherapy,
which further supports the primary results of the logis-
tic regression with the likelihood of mania-related vis-
its in the 12 months as an outcome. Furthermore, both
AD monotherapy and AD–MS combination therapy
were found to be more effective than MS monotherapy
in reducing the number of depression-related visits and
lengthening the time to ﬁrst depression-related visit.
This is clinically justiﬁable because AD is used prima-
rily for the purpose of treating depressive symptoms.
The propensity score method in the study included
more variables to better represent the disease severity
of bipolar disorder in the ﬁrst-stage predictive model
(Table 2) without the problem of overparameteriza-
tion in the second-stage outcome model. These varia-
bles were included also to further balance the disease
severity between the comparison groups to further
control for the potential prescribing bias. In addition,
quarters of treatment initiation were included in the
ﬁrst-stage predictive model to balance the seasonal
variation, which is a common phenomenon for psychi-
atric disorders [21,22].
Table 2 Propensity score matching results for comparison between antidepressant monotherapy and mood stabilizer monotherapy
Prematching Postmatching
AD only
(n = 2096)
MS only
(n = 504) P-value
AD only
(n = 347)
MS only
(n = 347) P-value
Age at treatment initiation (years, %)
Age 1: 18–24 10.6 8.3 9.2 9.2
Age 2: 25–34 25.8 20.0 21.6 23.6
Age 3: 35–44 31.2 25.6 26.5 28.0
Age 4: 45–54 22.9 29.6 27.7 25.4
Age 5: 55–64 9.6 16.5 <0.001 15.0 13.8 0.92
Sex (%)
Female 61.8 55.4 <0.01 56.5 58.5 0.59
Insurance plan type (%)
PPO 51.2 42.7 45.2 47.6
HMO 32.4 36.3 33.3 32.9
POS 8.0 9.5 10.1 9.8
Others 8.4 11.5 <0.01 11.5 9.8 0.87
Geographic region (%)
Mid Atlanta 36.2 31.0 30.0 33.7
New England 30.8 41.3 38.9 36.6
Others 33.0 27.8 <0.001 31.1 29.7 0.57
Use of tricyclics and MAOIs (%) 7.8 12.1 <0.01 10.4 11.0 0.81
Use of antipsychotics (%) 15.8 12.9 0.10 12.1 14.7 0.32
Use of benzodiazepines (%) 30.2 24.8 <0.05 26.2 24.2 0.54
Use of psychotherapy or ECT (%) 50.3 72.0 <0.001 67.4 70.0 0.46
Type of medical provider (%)
General/family practitioner 14.1 6.8 8.4 8.4
Internal medicine specialist 15.7 8.3 9.5 9.2
Psychiatrist 21.1 34.3 33.7 35.7
Others 49.1 50.6 <0.001 48.4 46.7 0.95
Selected comorbidities (%)
Neurotic disorders 44.5 23.4 <0.001 26.2 29.1 0.40
Personality disorder 6.8 5.6 0.32 5.8 6.6 0.64
Alcohol abuse/dependence 9.2 5.8 <0.05 6.3 7.5 0.55
Drug abuse/dependence 6.7 6.2 0.67 5.2 6.6 0.42
Other mental disorders 32.0 23.6 <0.001 25.4 28.0 0.44
Diabetes 5.6 4.4 0.26 5.2 4.9 0.86
Charlson comorbidity index score 0.492 0.399 0.05 0.452 0.427 0.75
Miscoding-related variables (%)
Without pure bipolar codes* 65.5 13.9 <0.001 18.2 18.7 0.84
With bipolar depressive codes* 6.8 45.4 <0.001 23.6 28.2 0.17
Quarter of treatment initiation (%)
Quarter 1 25.1 24.4 21.3 24.8
Quarter 2 29.6 31.2 33.4 31.7
Quarter 3 23.7 23.0 24.2 24.2
Quarter 4 21.7 21.4 0.93 21.0 19.3 0.73
Preindex bipolar severity
Number of mania-related visits 0.07 0.46 <0.001 0.29 0.28 0.90
Number of any bipolar visits 0.50 1.31 <0.001 1.18 1.22 0.81
Log of bipolar-related costs 1.76 4.39 <0.001 4.08 4.06 0.91
Log of total health-care costs 5.90 6.20 <0.01 6.21 6.28 0.60
*Pure bipolar codes: 296.0, 296.1, 296.4–296.8; pure bipolar depressive codes: 296.5, 296.82.
Notes: AD only, antidepressant monotherapy; MS only, mood stabilizer monotherapy; AD–MS, antidepressant–mood stabilizer combination therapy. Chi-square tests were cal-
culated for categorical variables and t-tests were calculated for continuous variables.
AD, antidepressant; ECT, electroconvulsive therapy; HMO, health maintenance organization; MAOIs, monoamine oxidase inhibitors; POS, point of service; PPO, preferred pro-
vider organization.
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A recently published article [23] based on the eld-
erly patients provided similar clinical indications for
AD. Second-generation ADs, however, were not differ-
entiated from the ﬁrst-generation tricyclics in that
study. The reference arm were patients who did not
receive an AD, which could comprise patients with any
other types of treatment, including no treatment. Hav-
ing MS monotherapy as the reference group and focus-
ing on adults between the age of 18 and 64 years, the
results of the present study provide important infor-
mation on the impact of second-generation AD medi-
cation use for bipolar depression. Nonetheless, the
results are limited by the study design. First, this study
used an intent-to-treat approach for which the treat-
ment type was deﬁned based on patients’ ﬁrst month of
prescriptions. It is possible that patients may have dis-
continued the initial treatment and/or switched to
other treatment type in the follow-up period, although
such a phenomenon happens in randomized clinical
trials too. As a sensitivity analysis, types of treatment
Table 3 Logit models on probabilities of having mania-related visits with propensity score matching, odds ratios (with 95% conﬁdence
intervals)
Comparison one: AD only vs. MS only
(n = 694)
Comparison two: AD–MS vs. MS only
(n = 756)
AD only (or AD–MS) 0.67 (0.42, 1.04) 0.99 (0.69, 1.43)
MS only (reference)
Mania-related visits before index 34.58 (18.02, 66.37)*** 1.77 (1.03, 3.02)*
Age categories
Age 1: 18–24 (reference)
Age 2: 25–34 1.01 (0.35, 2.92) 0.92 (0.44, 1.94)
Age 3: 35–44 0.69 (0.23, 2.00) 0.89 (0.44, 1.81)
Age 4: 45–54 1.48 (0.53, 4.17) 1.36 (0.68, 2.72)
Age 5: 55–64 1.19 (0.39, 3.71) 1.44 (0.65, 3.18)
Female (reference: male) 0.95 (0.57, 1.59) 0.93 (0.63, 1.36)
Insurance plan type
HMO 1.16 (0.62, 2.14) 0.90 (0.56, 1.44)
POS 0.82 (0.29, 2.28) 1.22 (0.61, 2.46)
PPO (reference)
Other insurance 0.75 (0.32, 1.78) 0.85 (0.42, 1.71)
Geographic region
Middle Atlantic 2.43 (1.19, 4.99)* 1.32 (0.79, 2.23)
New England 1.77 (0.90, 3.51) 1.31 (0.81, 2.12)
All other regions (reference)
Use of tricyclics and MAOIs 1.44 (0.64, 3.23) 1.19 (0.68, 2.10)
Use of antipsychotics 2.13 (1.13, 4.00)* 1.85 (1.16, 2.94)**
Use of benzodiazepines 1.23 (0.70, 2.18) 1.06 (0.69, 1.64)
Use of psychotherapy or ECT 2.44 (1.27, 4.68)** 2.94 (1.65, 5.24)***
Type of medical provider
General/family practitioner 1.17 (0.45, 3.03) 1.05 (0.49, 2.27)
Internal medicine specialist 1.70 (0.66, 4.39) 0.63 (0.28, 1.41)
Psychiatrist (reference)
Others 0.82 (0.46, 1.47) 1.02 (0.68, 1.54)
Selected comorbidities
Neurotic disorders 0.71 (0.39, 1.31) 0.81 (0.53, 1.24)
Personality disorder 0.59 (0.17, 2.02) 1.33 (0.64, 2.78)
Alcohol abuse/dependence 0.42 (0.09, 2.01) 1.13 (0.51, 2.50)
Drug abuse/dependence 0.81 (0.22, 3.03) 1.20 (0.54, 2.68)
Other mental disorders 1.39 (0.80, 2.43) 1.21 (0.80, 1.84)
Diabetes 1.92 (0.70, 5.25) 0.88 (0.33, 2.38)
Charlson comorbidity index score 1.07 (0.87, 1.31) 1.08 (0.94, 1.24)
*P < 0.05, **P < 0.01, ***P < 0.001.
Notes: AD only, antidepressant monotherapy; MS only, mood stabilizer monotherapy; AD–MS, antidepressant–mood stabilizer combination therapy.
AD, antidepressant; ECT, electroconvulsive therapy; HMO, health maintenance organization; MAOIs, monoamine oxidase inhibitors; PPO, preferred provider organization; POS,
point of service.
Table 4 Summary of second-generation antidepressant effects with propensity score matching (95% conﬁdence intervals)
Comparison One:
AD only vs. MS only
(n = 694)
Comparison Two:
AD–MS vs. MS only
(n = 756)
Logit models on probabilities of having mania-related visits, odds ratios 0.67 (0.42, 1.04) 0.99 (0.69, 1.43)
Negative binomial models on number of depression-related visits, incidence rate ratios 0.68 (0.56, 0.82)* 0.65 (0.52, 0.81)**
Cox models on time to ﬁrst mania-related visit, hazard ratios 0.83 (0.60, 1.16) 1.08 (0.82, 1.41)
Cox models on time to ﬁrst depression-related visit, hazard ratios 0.55 (0.44, 0.68)** 0.59 (0.48, 0.73)**
*P < 0.01, **P < 0.001.
Notes: AD only, antidepressant monotherapy; MS only, mood stabilizer monotherapy; AD–MS, antidepressant–mood stabilizer combination therapy. Controlled variables
included demographic, clinical-related, and health-related covariates. Please see Appendices for a detailed list of controlled variables and coefﬁcients.
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were redeﬁned according to patients’ ﬁrst 2 to
6 months of prescriptions. Similar study results were
achieved but with a much smaller sample size. Second,
this study used a 3-month washout period to provide
some reasonable assurance of the start of a medication
treatment. A 3-month period was used because the
existing literature recognizes that bipolar depression
episodes generally last for at least 2 to 3 months [24].
A longer washout period of, say, 6 months was con-
sidered, but it would have decreased the sample size
dramatically. Third, the index date was deﬁned by
either the ﬁrst MS use coupled with a depressive diag-
nosis or the ﬁrst second-generation AD use after the
washout period. There could potentially be dissimilar-
ities between the patients having depressive diagnosis
as index and those having AD use as index, as patients
with MS monotherapy would never have an AD use as
index by design. Nonetheless, because all the charac-
teristics between the comparison groups were balanced
after propensity score matching, we are conﬁdent that
the study results should be valid. Fourth, although we
included variables to better represent the disease sever-
ity of bipolar disorder during propensity score match-
ing, the absence of better ratings, such as CGI-BP scale,
could still limit our study results.
Based on the deﬁnition of bipolar disorder, if one
manic or hypomanic episode has been observed in a
patient, any depression-related diagnosis after such
an episode should deﬁnitively be bipolar depression
rather than MDD [1]. In fact, before the recognition of
manic or hypomanic symptoms, a depressive symptom
could be either bipolar depressive or major depressive.
The literature indicated that, on average, a correct
diagnosis of bipolar disorder is made 8 to 10 years
after the onset of symptoms [25]. Knowing that bipo-
lar depression is often underdiagnosed or miscoded as
MDD, we developed an algorithm to guard against a
false negative coding (i.e., bipolar depression coded as
MDD). Any MDD diagnoses (296.2, 296.3, 311) that
occurred after a bipolar or mania-related diagnosis
(296.0, 296.1, 296.4–296.8) or earlier but no more
than 90 days [24] before the bipolar or mania-related
diagnosis were deemed a miscoding and considered
bipolar depression [26].
For the same reason, our sample consisted of more
patients on AD monotherapy than the usual treatment
pattern in the United States. Many patients in our sam-
ple were treated with AD monotherapy after a mis-
coded MDD diagnosis (71% of the diagnosis-indexed
patients with AD monotherapy and 57% with MS
monotherapy), which would be truly bipolar depres-
sion based on our miscode guarding algorithm. This
group of patients is less severe with bipolar symptoms
as their descriptive statistics indicated. This reason
could also contribute to the slightly better results of the
AD monotherapy than the AD–MS combination ther-
apy, although it is not the purpose of the study to com-
pare these two. Less severe bipolar patients have lower
symptomatic frequency, which makes it more difﬁcult
to identify dual depressive and manic features. Hence,
these patients are more likely to receive a diagnosis of
MDD rather than bipolar depression. Without arguing
too much of the correctness of such an algorithm, we
must acknowledge that with its purpose to guard
against the miscoding, this algorithm might be a limi-
tation of the study design itself, too.
We used 1:1 greedy matching for the propensity
score method. The advantage is its simplicity and intu-
itive appeal. It is robust to the functional form of the
conditional expectations and hence allows arbitrary
heterogeneity of the effects in the population. A simu-
lation suggests that matching on the propensity score is
best when there are more than 20 covariates [27].
Practically, 1:1 greedy matching usually reduces the
original sample size considerably, like the case in our
study. Such a phenomenon can be conceived as apply-
ing the selection criteria in a randomized clinical trial.
Internal validity is considered ﬁrst rather than external
validity. Avoiding bias is more important and should
be given priority over efﬁciency of the estimates [28].
Nonetheless, it should be noted that the matched sam-
ples are different from the unmatched ones. In our
study, less-severe patients with AD monotherapy were
left out because of the propensity score matching. The
study results were more applicable for the relatively
severe patients.
This study focused only on the group effect of sec-
ond-generation ADs. It is possible that the prescription
distributions of ADs are not similar between treatment
types, which may lead to skewed conclusions. For
example, if most of the ADs in AD monotherapy were
bupropion and most of the ADs in combination ther-
apy were venlafaxine, the comparison would be mean-
ingless. Therefore, we further checked the second-
generation AD distributions in different treatment
types (Table 5) and found that they are quite compa-
rable for most medications.
Table 5 Second-generation antidepressants included in the
study according to treatment types
Antidepressant medications
Treatment types
AD only (%) AD–MS (%)
Bupropion 18.7 25.4
Citalopram 14.5 15.2
Fluoxetine 15.3 12.8
Fluvoxamine 0.8 1.1
Mirtazapine 1.9 3.6
Nefazodone 3.8 3.8
Paroxetine 19.0 14.5
Sertraline 19.9 13.0
Trazodone 9.4 15.4
Venlafaxine 6.4 8.9
Notes: AD only, antidepressant monotherapy; AD–MS, antidepressant–mood stabi-
lizer combination therapy.
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The study is based on a claims database, in which
the disease symptoms are recognized and recorded by
ICD-9 diagnosis codes rather than symptom descrip-
tive texts in medical charts. It is possible that physi-
cians or psychiatrists may not have assigned ICD-9
codes correctly and it would have been preferred if the
ICD-9 codes could be validated by medical chart
reviews.
Because of the available data and the follow-up
time limitation, it is likely that our study included
bipolar patients with relatively rapid symptomatic
cycles. Patients whose symptoms occur less frequently,
say, once every 2 years, would have been less likely to
be observed in the data and less likely to be included in
the study. In addition, although administrative data-
bases provide a readily available source of information
on large patient populations, there may be problems
with the generalizability of the results because of the
homogeneity of the insured population in the study.
Conclusion
This study presents empirical evidence on the relation-
ship between second-generation AD medication use
and mania- and depression-related health outcomes
for patients with bipolar depression in a national sam-
ple of insured patients. Monotherapy with second-
generation ADs was not found to be associated with
either a higher likelihood of having mania-related vis-
its or shorter time to next mania-related visit in bipolar
depressed patients. This relationship also held for
AD–MS combination therapy. Thus, our study does
not support a risk of induced manic-switching with
second-generation AD treatment. In addition, both
second-generation AD monotherapy and AD–MS
combination therapy were shown to decrease the
number of depression-related visits, further supporting
the efﬁcacy of this type of treatment. Although the evi-
dence from the study supports a favorable risk–beneﬁt
proﬁle, more evidence from other populations includ-
ing randomized clinical trials is needed to further
establish the safety and efﬁcacy of second-generation
ADs in treating bipolar depression.
We are grateful to Drs. Susan L. Hogue, Steven P. Burch, and
Thomas R. Thompson of GlaxoSmithKline for the access of
data and their advice.
Source of ﬁnancial support: No funding was received for this
project. Dr. Hansen is supported by grant K12 RR023248.
References
1 Goodwin FK, Jamison KR. Manic-Depressive Illness
(2nd ed.). New York: Oxford University Press, 1990.
2 Woods SW. The economic burden of bipolar disease.
J Clin Psychiatry 2000;61(Suppl. 13):38–41.
3 Kleinman L, Lowin A, Flood E, et al. Costs of bipolar
disorder. Pharmacoeconomics 2003;21:601–22.
4 Murray CJL, Lopez AD. The Global Burden of Dis-
ease. World Heath Organization. Cambridge, MA:
Harvard University Press, 1996.
5 Judd LL, Akiskal HS, Schettler PJ, et al. The long-
term natural history of the weekly symptomatic status
of bipolar I disorder. Arch Gen Psychiatry 2002;
59:530–7.
6 Fu AZ, Krishnan AA, Harris SD, et al. The economic
burden of bipolar-related depression versus mania
phases. Drug Beneﬁt Trends 2004;16:569–75.
7 Vojta C, Kinosian B, Glick H, et al. Self-reported
quality of life across mood states in bipolar disorder.
Compr Psychiatry 2001;42:190–5.
8 Keller MB, Baker LA. Bipolar disorder: epidemiology,
course, diagnosis, treatment. Bull Menninger Clin
1991;55:172–81.
9 Compton MT, Nemeroff CB. The treatment of bipo-
lar depression. J Clin Psychiatry 2000;61:57–67.
10 Sachs GS, Printz DJ, Kahn DA, et al. The Expert
Consensus Guideline Series: medication treatment of
bipolar disorder 2000. Postgrad Med 2000;Spec
No:1–104.
11 American Psychiatric Association. Practice guideline
for the treatment of patients with bipolar disorder
(revision). Am J Psychiatry 2002;159(4 Suppl.):S1–
50.
12 Moller HJ, Grunze H. Have some guidelines for the
treatment of acute bipolar depression gone too far in
the restriction of antidepressants? Eur Arch Psychia-
try Clin Neurosci 2000;250:57–68.
13 Ghaemi SN, Hsu DJ, Soldani F, et al. Antidepressants
in bipolar disorder: the case for caution. Bipolar Dis-
ord 2003;5:421–33.
14 Andersen RM. Revisiting the behavioral model and
access to medical care: does it matter? J Health Soc
Behav 1995;36:1–10.
15 Goodwin FK, Fireman B, Simon GE, et al. Suicide risk
in bipolar disorder during treatment with lithium and
divalproex. JAMA 2003;290:1467–73.
16 Charlson ME, Pompei P, Ales KL, et al. A new
method of classifying prognostic comorbidity in lon-
gitudinal studies: development and validation. J
Chron Dis 1987;40:373–83.
17 Cassidy F, Ahearn E, Carroll BJ. Elevated frequency
of diabetes mellitus in hospitalized manic-depressive
patients. Am J Psychiatry 1999;156:1417–20.
18 Parsons LS. Reducing Bias in a Propensity Score
Matched-Pair Sample Using Greedy Matching Tech-
niques. SAS Users Group International (SUGI) 26th
conference, paper 214–26. April 22–25, 2001.
19 Ghaemi SN, Lenox MS, Baldessarini RJ. Effective-
ness and safety of long-term antidepressant treat-
ment in bipolar disorder. J Clin Psychiatry 2001;62:
565–9.
20 Calabrese JR, Rapport DJ, Shelton MD, et al. Clinical
studies on the use of lamotrigine in bipolar disorder.
Neuropsychobiology 1998;38:185–91.
21 Shin K, Schaffer A, Levitt AJ, et al. Seasonality in a
community sample of bipolar, unipolar and control
subjects. J Affect Disord 2005;86:19–25.
Fu et al.136
22 Kim CD, Lesage AD, Seguin M, et al. Seasonal differ-
ences in psychopathology of male suicide completers.
Compr Psychiatry 2004;45:333–9.
23 Schaffer A, Mamdani M, Levitt A, et al. Effect of
antidepressant use on admissions to hospital among
elderly bipolar patients. Int J Geriatr Psychiatry
2006;21:275–80.
24 Frankle WG, Perlis RH, Deckersbach T, et al. Bipolar
depression: relationship between episode length and
antidepressant treatment. Psychol Med 2002;32:
1417–23.
25 Suppes T, Leverich GS, Keck PE, et al. The Stanley
foundation bipolar treatment outcome network. II.
Demographics and illness characteristics of the ﬁrst
261 patients. J Affect Disord 2001;67:45–59.
26 Fu AZ, Christensen DB, Hansen RA, et al. Second-
generation antidepressant discontinuation on
depressive relapse in adult patients with bipolar
depression: a retrospective analysis. Clin Ther
2006;28:979–89.
27 Gu XS, Rosenbaum PR. Comparison of multivariate
matching methods: structures, distances and algo-
rithms. J Comput Graph Stat 1993;2:405–20.
28 Dehejia RH, Wahba S. Propensity score-matching
methods for nonexperimental causal studies. Rev
Econ Stat 2002;84:151–61.
Supplementary material for this article can be found at: http://www.ispor.org/publications/value/
VIHsupplementary.asp
